 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
101:935-940
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity.
|
|
S.K.Olsen,
O.A.Ibrahimi,
A.Raucci,
F.Zhang,
A.V.Eliseenkova,
A.Yayon,
C.Basilico,
R.J.Linhardt,
J.Schlessinger,
M.Mohammadi.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The prototypical fibroblast growth factor receptor (FGFR) extracellular domain
consists of three Ig domains (D1-D3) of which the two membrane-proximal D2 and
D3 domains and the interconnecting D2-D3 linker bear the determinants of ligand
binding and specificity. In contrast, D1 and the D1-D2 linker are thought to
play autoinhibitory roles in FGFR regulation. Here, we report the crystal
structure of the three-Ig form of FGFR3c in complex with FGF1, an FGF that binds
promiscuously to each of the seven principal FGFRs. In this structure, D1 and
the D1-D2 linker are completely disordered, demonstrating that these regions are
dispensable for FGF binding. Real-time binding experiments using surface plasmon
resonance show that relative to two-Ig form, the three-Ig form of FGFR3c
exhibits lower affinity for both FGF1 and heparin. Importantly, we demonstrate
that this autoinhibition is mediated by intramolecular interactions of D1 and
the D1-D2 linker with the minimal FGF and heparin-binding D2-D3 region. As in
the FGF1-FGFR2c structure, but not the FGF1-FGFR1c structure, the alternatively
spliced betaC'-betaE loop is ordered and interacts with FGF1 in the FGF1-FGFR3c
structure. However, in contrast to the FGF1-FGFR2c structure in which the
betaC'-betaE loop interacts with the beta-trefoil core region of FGF1, in the
FGF1-FGFR3c structure, this loop interacts extensively with the N-terminal
region of FGF1, underscoring the importance of the FGF1 N terminus in conferring
receptor-binding affinity and promiscuity. Importantly, comparison of the three
FGF1-FGFR structures shows that the flexibility of the betaC'-betaE loop is a
major determinant of ligand-binding specificity and promiscuity.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. The FGFR3c-FGF1 structure. (A) A ribbon
representation of the FGFR3c-FGF1 complex. FGF1 is orange,
FGFR3c D2 is green, D3 is cyan, and the D2-D3 linker is black.
The alternatively spliced C-terminal half of D3 is purple. The N
and C termini of FGF1 are labeled NT and CT, respectively. The
FGF1 N-terminal region not included in the truncated FGF1
construct used in the FGFR1c and FGFR2c structures is gray.
(Inset) Protein from FGF1-FGFR3c crystals is indistinguishable
from the freshly purified complex. SDS/PAGE analysis of the
purified three-Ig form FGFR3c-FGF1 complex (1), the purified
two-Ig form FGFR3c-FGF1 complex (2), the protein solution from a
FGF1-FGFR3c crystal containing hanging drop (3), and dissolved
FGF1-FGFR3c crystals (4) (washed twice). Lanes with molecular
mass markers are labeled M, and selected molecular masses are
labeled. (B) Structure-based sequence alignment of Ig domain 3
from human FGFRs. The sequence alignment was performed by using
CLUSTALW (28). The location and length of the strands
are shown on top of the sequence alignment. Note that the C' strand
of FGFR3c terminates two residues earlier than those of FGFR1c
and FGFR2c, and, therefore, the C'- E loop of FGFR3 is 12
residues long (residues 310-322). The different lengths of the
C'-
E
loops of FGFR1c and FGFR2c from the FGF1-FGFR structures are
indicated by boxes within the alignment. A period indicates
sequence identity to FGFR3c. A dash represents a gap introduced
to optimize the alignment. The alternatively spliced C-terminal
half of D3 is marked by red arrows. FGFR3c residues that
interact with FGF1 are red. FGFR1c and FGFR2c residues that
interact with FGF in other crystal structures are cyan. (C)
Superimposition of FGFR3c and FGFR2c D3. The C^ trace of
FGFR2c D3 from the FGFR2c-FGF1 structure (cyan) was superimposed
onto the C^ trace of FGFR3c D3 from
the FGFR3c-FGF1 structure (orange; rms deviation = 0.831
Å). Residues corresponding to the C- C' and C'- E loops
were not included in the superimposition. The B'- C, C'- E, and
F-
G
loops of the D3s are marked by an arrowhead. (D) Interactions
between the FGF1 N terminus and D3 in the FGFR3c-FGF1 structure.
Colors are as in A. Selected residues are labeled and are
rendered in a stick format. This figure was created by using the
program PYMOL (29).
|
 |
Figure 3.
Fig. 3. D1 and the D1-D2 linker negatively regulate ligand-
and heparin-binding affinity of FGFR3c. (A and B) Sensorgrams of
the two-versus three-Ig form of FGFR3c binding to full-length
FGF1. Analyte concentrations are colored as follows: purple (1.6
µM), green (0.8 µM), red (0.4 µM), blue
(0.2µM), and gray (0.1 µM). (C and D) Sensorgrams of
the two-versus three-Ig form of FGFR3c binding to heparin.
Analyte concentrations are colored as follows: purple (5
µM), yellow (2.5 µM), orange (1.25 µM), red
(0.625 µM), and cyan (0.313 µM). (E) Sensorgram of
D1+ binding to the two-Ig form of FGFR3c. Analyte concentrations
are colored as follows: purple (10 µM), pink (5 µM), yellow (2.5
µM), and cyan (1 µM).
|
 |
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
Literature references that cite this PDB file's
key reference
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.L.Roca,
Y.Ishida,
N.Nikolaidis,
S.O.Kolokotronis,
S.Fratpietro,
K.Stewardson,
S.Hensley,
M.Tisdale,
G.Boeskorov,
and
A.D.Greenwood
(2009).
Genetic variation at hair length candidate genes in elephants and the extinct woolly mammoth.
|
| |
BMC Evol Biol, 9,
232.
|
 |
|
|
|
|
 |
J.Qing,
X.Du,
Y.Chen,
P.Chan,
H.Li,
P.Wu,
S.Marsters,
S.Stawicki,
J.Tien,
K.Totpal,
S.Ross,
S.Stinson,
D.Dornan,
D.French,
Q.R.Wang,
J.P.Stephan,
Y.Wu,
C.Wiesmann,
and
A.Ashkenazi
(2009).
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
|
| |
J Clin Invest, 119,
1216-1229.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Li,
C.Christensen,
L.B.Køhler,
V.V.Kiselyov,
V.Berezin,
and
E.Bock
(2009).
Agonists of fibroblast growth factor receptor induce neurite outgrowth and survival of cerebellar granule neurons.
|
| |
Dev Neurobiol, 69,
837-854.
|
 |
|
|
|
|
 |
A.Kochoyan,
F.M.Poulsen,
V.Berezin,
E.Bock,
and
V.V.Kiselyov
(2008).
Structural basis for the activation of FGFR by NCAM.
|
| |
Protein Sci, 17,
1698-1705.
|
 |
|
|
|
|
 |
B.M.Riley,
M.A.Mansilla,
J.Ma,
S.Daack-Hirsch,
B.S.Maher,
L.M.Raffensperger,
E.T.Russo,
A.R.Vieira,
C.Dodé,
M.Mohammadi,
M.L.Marazita,
and
J.C.Murray
(2007).
Impaired FGF signaling contributes to cleft lip and palate.
|
| |
Proc Natl Acad Sci U S A, 104,
4512-4517.
|
 |
|
|
|
|
 |
M.Roghani,
and
D.Moscatelli
(2007).
Prostate cells express two isoforms of fibroblast growth factor receptor 1 with different affinities for fibroblast growth factor-2.
|
| |
Prostate, 67,
115-124.
|
 |
|
|
|
|
 |
P.Aloy,
and
R.B.Russell
(2006).
Structural systems biology: modelling protein interactions.
|
| |
Nat Rev Mol Cell Biol, 7,
188-197.
|
 |
|
|
|
|
 |
S.Heuertz,
M.Le Merrer,
B.Zabel,
M.Wright,
L.Legeai-Mallet,
V.Cormier-Daire,
L.Gibbs,
and
J.Bonaventure
(2006).
Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia.
|
| |
Eur J Hum Genet, 14,
1240-1247.
|
 |
|
|
|
|
 |
S.K.Olsen,
J.Y.Li,
C.Bromleigh,
A.V.Eliseenkova,
O.A.Ibrahimi,
Z.Lao,
F.Zhang,
R.J.Linhardt,
A.L.Joyner,
and
M.Mohammadi
(2006).
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain.
|
| |
Genes Dev, 20,
185-198.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
V.V.Kiselyov,
A.Kochoyan,
F.M.Poulsen,
E.Bock,
and
V.Berezin
(2006).
Elucidation of the mechanism of the regulatory function of the Ig1 module of the fibroblast growth factor receptor 1.
|
| |
Protein Sci, 15,
2318-2322.
|
 |
|
|
|
|
 |
V.V.Kiselyov,
E.Bock,
V.Berezin,
and
F.M.Poulsen
(2006).
NMR structure of the first Ig module of mouse FGFR1.
|
| |
Protein Sci, 15,
1512-1515.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
O.A.Ibrahimi,
B.K.Yeh,
A.V.Eliseenkova,
F.Zhang,
S.K.Olsen,
M.Igarashi,
S.A.Aaronson,
R.J.Linhardt,
and
M.Mohammadi
(2005).
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization.
|
| |
Mol Cell Biol, 25,
671-684.
|
 |
|
|
|
|
 |
R.L.Rich,
and
D.G.Myszka
(2005).
Survey of the year 2004 commercial optical biosensor literature.
|
| |
J Mol Recognit, 18,
431-478.
|
 |
|
|
|
|
 |
C.Dodé,
and
J.P.Hardelin
(2004).
Kallmann syndrome: fibroblast growth factor signaling insufficiency?
|
| |
J Mol Med, 82,
725-734.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|